Ceapro (CZO.V) Stock Price

Ceapro Price

Delisted

Revenue has compounded at 8.8% per year over the past 19 years to 9.63 M CAD. Earnings per share have grown at 16.6% per year over the last 12 years. Ceapro's net margin stands at -48.9%, down from -8.8% several years earlier.

Ceapro stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Ceapro over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ceapro stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ceapro's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Ceapro Stock Price History
DateCeapro Price
Access this data via the Eulerpool API

Ceapro Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
12.93 M CAD
2.66 M CAD
-958,275.00 CAD
Jan 1, 2018
11.59 M CAD
128,078.00 CAD
-315,537.00 CAD
Jan 1, 2019
12.88 M CAD
-734,294.00 CAD
-1.13 M CAD
Jan 1, 2020
15.12 M CAD
2.12 M CAD
1.86 M CAD
Jan 1, 2021
17.20 M CAD
2.42 M CAD
3.37 M CAD
Jan 1, 2022
18.84 M CAD
5.31 M CAD
4.40 M CAD
Jan 1, 2023
9.63 M CAD
-6.26 M CAD
-4.71 M CAD
Jan 1, 2024 (e)
24.99 M CAD
0.00 CAD
0.00 CAD

Ceapro Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 27, 2026, 10:03 PM
 
REVENUEM CAD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CAD
EBITM CAD
EBIT MARGIN%
NET INCOMEM CAD
NET INCOME GROWTH%
SHARESM
2009201020112012201320142015201620172018201920202021202220232024e
4.005.005.005.006.008.0010.0013.0012.0011.0012.0015.0017.0018.009.0024.00
25.0020.0033.3325.0030.00-7.69-8.339.0925.0013.335.88-50.00166.67
50.0040.0060.0040.0050.0050.0070.0069.2358.3354.5541.6746.6752.9461.1133.3333.33
2.002.003.002.003.004.007.009.007.006.005.007.009.0011.003.008.00
1.003.005.002.002.002.005.00-6.00
12.5030.0038.4616.6713.3311.7627.78-66.67
1.004.003.00-1.001.003.004.00-4.00
300.00-25.00-200.00200.0033.33-200.00
51.7156.5160.2860.2862.0261.5465.6876.8375.7177.0577.8878.7178.3378.2378.2978.29
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Ceapro generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ceapro retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ceapro's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Ceapro has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ceapro's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Ceapro stock margins

The Ceapro margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ceapro. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ceapro.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
56.26 %
20.55 %
-7.41 %
Jan 1, 2018
52.95 %
1.10 %
-2.72 %
Jan 1, 2019
42.28 %
-5.70 %
-8.79 %
Jan 1, 2020
50.41 %
13.99 %
12.27 %
Jan 1, 2021
56.35 %
14.05 %
19.57 %
Jan 1, 2022
58.48 %
28.21 %
23.34 %
Jan 1, 2023
41.07 %
-64.93 %
-48.89 %
Jan 1, 2024 (e)
41.07 %
0.00 %
0.00 %

Ceapro Stock Revenue, EBIT, Earnings per Share

The Ceapro earnings per share therefore indicates how much revenue Ceapro has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0.17 CAD
0.04 CAD
-0.01 CAD
Jan 1, 2018
0.15 CAD
0.00 CAD
-0.00 CAD
Jan 1, 2019
0.17 CAD
-0.01 CAD
-0.01 CAD
Jan 1, 2020
0.19 CAD
0.03 CAD
0.02 CAD
Jan 1, 2021
0.22 CAD
0.03 CAD
0.04 CAD
Jan 1, 2022
0.24 CAD
0.07 CAD
0.06 CAD
Jan 1, 2023
0.12 CAD
-0.08 CAD
-0.06 CAD
Jan 1, 2024 (e)
0.32 CAD
0.00 CAD
0.00 CAD

Ceapro business model & stock analysis

Ceapro Inc is an innovative biotechnology company based in Edmonton, Canada. The company was founded in 1997 and has since specialized in the development of natural, biological ingredients from plants. It is listed on the Toronto Stock Exchange and has become a key player in the field of natural-based medicine and cosmetics in recent years. Ceapro's business model is based on the research and production of active compounds from plant-based raw materials. The company employs gentle extraction methods that preserve the effectiveness of the ingredients and enable environmentally friendly production. Ceapro collaborates closely with research and industry to ensure the best possible effectiveness and applicability of its products. The company's products are divided into various segments tailored to the needs of customers. One important segment is medicine, where Ceapro focuses on the development of herbal remedies. The company has already developed some promising products in this area, which can be used, for example, for inflammation, pain, or diabetes. Another important segment of Ceapro is cosmetics, where the company researches and produces natural ingredients for skin and hair care. These products are known for their high effectiveness, tolerability, and environmental friendliness. One of the company's most famous products is Avenanthramide, an ingredient derived from oats that offers anti-aging and anti-inflammatory properties. Ceapro also places special emphasis on the development of digestive-aid ingredients that can be used in the food industry. The company relies on plant enzymes and compounds that help support and relieve the digestive system. The use of natural ingredients ensures high tolerability and usability. Over the course of its history, Ceapro Inc has already won numerous awards and prizes that confirm the high quality of its products and the company's innovative power. For example, the company has been repeatedly honored with the Alberta Venture Fast Growth 50 Award and also received the Environmental Stewardship Award from the Edmonton Chamber of Commerce. Ceapro is not only an innovative biotechnology company specializing in the research and production of plant-based ingredients but also an important player in the fields of medicine and cosmetics. The company employs gentle extraction methods and collaborates closely with research and industry to achieve the best possible effectiveness and applicability. The different products are divided into the segments of medicine, cosmetics, and food and are known for their high effectiveness, tolerability, and environmental friendliness.

Ceapro SWOT Analysis

Strengths

Ceapro Inc has a strong research and development team that continually innovates and creates new products, giving the company a competitive edge in the market.

The company has a diverse product portfolio, offering a wide range of high-quality natural ingredients for various industries, including pharmaceuticals, cosmetics, and nutraceuticals.

Ceapro Inc has established strong relationships with key suppliers and distributors, allowing them to maintain a consistent supply chain and reach customers globally.

The company has a solid financial position, with steady revenue growth and profitability, enabling them to invest in research and development activities and expand their operations.

Weaknesses

Ceapro Inc relies heavily on a limited number of major customers, which poses a risk to the company if it were to lose any of these key accounts.

The company's global presence is relatively small compared to some competitors, limiting their market reach and potential for growth.

Ceapro Inc faces the challenge of maintaining consistent product quality and ensuring efficient manufacturing processes to meet market demand.

Opportunities

The rise in demand for natural and sustainable ingredients in various industries provides Ceapro Inc with an opportunity to capitalize on their expertise in producing such products.

Expansion into emerging markets, such as Asia-Pacific and Latin America, can help Ceapro Inc tap into new customer segments and further grow their business.

Collaborations with academic institutions and research organizations can enhance Ceapro Inc's research capabilities and lead to the development of innovative and differentiated products.

Threats

Intense competition in the natural ingredients market can erode Ceapro Inc's market share and pricing power if they fail to differentiate themselves effectively.

Economic downturns and fluctuations in currency exchange rates may impact the company's profitability, especially if it heavily relies on export markets.

Changes in regulations and compliance requirements in the markets Ceapro Inc operates in can pose challenges and increase costs for the company.

Ceapro Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Ceapro historical P/E ratio, EBIT multiple, and P/S ratio

Ceapro annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Ceapro shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
75.71 M Stocks
Jan 1, 2018
77.05 M Stocks
Jan 1, 2019
77.88 M Stocks
Jan 1, 2020
78.71 M Stocks
Jan 1, 2021
78.33 M Stocks
Jan 1, 2022
78.23 M Stocks
Jan 1, 2023
78.29 M Stocks
Jan 1, 2024 (e)
78.29 M Stocks

Ceapro stock splits

In Ceapro's history, there have been no stock splits.
Price targets and forecasts for Ceapro are not yet available.

Ceapro Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/29/2008-0.01CAD740,949.00CAD2007 Q4

Ceapro shareholder structure

% Name
2.27163%
Gagnon (Gilles R)
Gagnon (Gilles R)
1.46493%
Rourke (Glenn)
Rourke (Glenn)
0.12978%
Li (William W. M.D.)
Li (William W. M.D.)
0.10007%
Kosciessa (Ulrich)
Kosciessa (Ulrich)
0.04152%
Prefontaine (Stacy)
Prefontaine (Stacy)

Ceapro Executives and Management Board

GG

Mr. Gilles Gagnon

Chief Executive Officer, Director · since 2007

Compensation560,000.00 CAD
SP

Ms. Stacy Prefontaine

Chief Financial Officer

Compensation232,988.00 CAD
RM

Mr. Ronald Miller

Independent Chairman of the Board

Compensation96,060.00 CAD
GF

Ms. Genevieve Foster

Independent Director

Compensation92,378.00 CAD
WL

Dr. William Li

(60)

Independent Director

Compensation59,566.00 CAD

Ceapro Supply Chain

Ceapro Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#Name1M3M6M1Y2YTrend
1
0.17
0.68
0.23
0.67
2
0.59
0.53
0.74
0.09
3
0
0.57
0.70
0.73
4
0.08
0.38
-0.46
-0.44
5
0.58
0.20
0.54
-0.07

Frequently asked questions about Ceapro

The business model of Ceapro Inc revolves around the development and commercialization of innovative natural products derived from oats and other plant sources. Ceapro specializes in the extraction and purification of active ingredients for the pharmaceutical, cosmetic, and human health markets. By leveraging its proprietary technologies, Ceapro harnesses the power of nature to create high-value products that provide sustainable and renewable solutions. With a strong focus on research and development, Ceapro aims to deliver unique and effective products for a wide range of applications, catering to the growing demand for natural and environmentally friendly alternatives.

All fundamentals and in-depth analysis of Ceapro

Our stock analysis for Ceapro stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ceapro. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.